YBX1 and colorectal cancer: Thus, among the 47 genes, the NFAT5, S100A4, LMNB2, CITED2, YB-1, and TCF7L2 genes were identified as potential drug targets after the drug treatment in the HT29 cell lines, and they could also play a potential role in the epigenomics of colorectal cancer.